{"protocolSection": {"identificationModule": {"nctId": "NCT00738972", "nctIdAliases": ["NCT00621127"], "orgStudyIdInfo": {"id": "MK-0653A-168"}, "secondaryIdInfos": [{"id": "2008_020"}], "organization": {"fullName": "Fundaci\u00f3n Lindavista del Coraz\u00f3n AC", "class": "OTHER"}, "briefTitle": "Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)", "officialTitle": "Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients."}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "TERMINATED", "whyStopped": "Study terminated early due to sample size, not possible to perform further statistical analysis.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-19", "studyFirstSubmitQcDate": "2008-08-19", "studyFirstPostDateStruct": {"date": "2008-08-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-07-20", "resultsFirstSubmitQcDate": "2013-07-20", "resultsFirstPostDateStruct": {"date": "2013-08-13", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2011-08-16", "dispFirstSubmitQcDate": "2011-08-16", "dispFirstPostDateStruct": {"date": "2011-08-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-17", "lastUpdatePostDateStruct": {"date": "2013-08-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Fundaci\u00f3n Lindavista del Coraz\u00f3n AC", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "Evaluate pleiotropic effects of simvastatin in hypertensive patients."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan 80 mg + Paravastin 40 mg", "type": "ACTIVE_COMPARATOR", "description": "Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)", "interventionNames": ["Drug: valsartan", "Drug: pravastatin"]}, {"label": "Valsartan 80 mg + Simvastatin 40 mg", "type": "ACTIVE_COMPARATOR", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)", "interventionNames": ["Drug: valsartan", "Drug: simvastatin"]}, {"label": "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg", "type": "EXPERIMENTAL", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)", "interventionNames": ["Drug: valsartan", "Drug: ezetimibe (+) simvastatin"]}, {"label": "Valsartan 80 mg", "type": "ACTIVE_COMPARATOR", "description": "Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)", "interventionNames": ["Drug: valsartan"]}], "interventions": [{"type": "DRUG", "name": "valsartan", "description": "80 mg valsartan. Duration: 12 months. Tablets", "armGroupLabels": ["Valsartan 80 mg", "Valsartan 80 mg + Paravastin 40 mg", "Valsartan 80 mg + Simvastatin 40 mg", "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg"], "otherNames": ["Diovan"]}, {"type": "DRUG", "name": "pravastatin", "description": "40 mg pravastatin. Duration: 12 months. Tablets", "armGroupLabels": ["Valsartan 80 mg + Paravastin 40 mg"], "otherNames": ["Pravacol"]}, {"type": "DRUG", "name": "simvastatin", "description": "40 mg simvastatin. Duration: 12 months. Tablets", "armGroupLabels": ["Valsartan 80 mg + Simvastatin 40 mg"], "otherNames": ["Zocor", "MK0733"]}, {"type": "DRUG", "name": "ezetimibe (+) simvastatin", "description": "ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets", "armGroupLabels": ["Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg"], "otherNames": ["vytorin", "MK0653A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients", "description": "Left ventricular hypertrophy reduction was to be measured by echocardiography.", "timeFrame": "6 Month(s)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Females Or Males Over 18 Years Old\n* Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology\n* Left Ventricular hypertrophy Demonstrated By Echocardiography\n* Mild To Moderated hypercholesterolemia\n* Willing To Participate And Sign The Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Type 1 Or 2 Diabetes Mellitus\n* Familiar hypercholesterolemia\n* Low Density Lipoprotein-Cholesterol (LDL-C) \\> 190 mg/dl\n* History Of Myocardial Infarction Or Stable Chronic Angina\n* Triglycerides \\>250 mg/dl", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan 80 mg + Paravastin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)"}, {"id": "FG001", "title": "Valsartan 80 mg + Simvastatin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)"}, {"id": "FG002", "title": "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)"}, {"id": "FG003", "title": "Valsartan 80 mg", "description": "Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan 80 mg + Paravastin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)"}, {"id": "BG001", "title": "Valsartan 80 mg + Simvastatin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)"}, {"id": "BG002", "title": "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)"}, {"id": "BG003", "title": "Valsartan 80 mg", "description": "Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "11"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": ">18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients", "description": "Left ventricular hypertrophy reduction was to be measured by echocardiography.", "populationDescription": "This study was terminated early and due to sample size it was not possible to perform further statistical analyses.", "reportingStatus": "POSTED", "timeFrame": "6 Month(s)", "groups": [{"id": "OG000", "title": "Valsartan 80 mg + Paravastin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)"}, {"id": "OG001", "title": "Valsartan 80 mg + Simvastatin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)"}, {"id": "OG002", "title": "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)"}, {"id": "OG003", "title": "Valsartan 80 mg", "description": "Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan 80 mg + Paravastin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}, {"id": "EG001", "title": "Valsartan 80 mg + Simvastatin 40 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}, {"id": "EG002", "title": "Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg", "description": "Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}, {"id": "EG003", "title": "Valsartan 80 mg", "description": "Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 0, "otherNumAtRisk": 2}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was terminated early and due to sample size it was not possible to perform further statistical analyses."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Vice President, Late Stage Development Group Leader", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Mexico"]}, "conditionBrowseModule": {"meshes": [{"id": "D000017379", "term": "Hypertrophy, Left Ventricular"}, {"id": "D000006984", "term": "Hypertrophy"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M10035", "name": "Hypertrophy", "asFound": "Hypertrophy", "relevance": "HIGH"}, {"id": "M19658", "name": "Hypertrophy, Left Ventricular", "asFound": "Left Ventricular Hypertrophy", "relevance": "HIGH"}, {"id": "M22519", "name": "Pathological Conditions, Anatomical", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000019821", "term": "Simvastatin"}, {"id": "D000069438", "term": "Ezetimibe"}, {"id": "D000017035", "term": "Pravastatin"}], "ancestors": [{"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M409", "name": "Ezetimibe", "asFound": "Ropivacaine", "relevance": "HIGH"}, {"id": "M450", "name": "Ezetimibe, Simvastatin Drug Combination", "relevance": "LOW"}, {"id": "M21713", "name": "Simvastatin", "asFound": "GSK", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M19368", "name": "Pravastatin", "asFound": "Behavior Therapy", "relevance": "HIGH"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}